These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6889865)

  • 1. Toxicity of cisplatin and hydroxymalonatodiammine platinum (II) towards mouse bone marrow and B16 melanoma in relation to DNA binding in vivo.
    Pera MF; Sessford D; Roberts JJ
    Biochem Pharmacol; 1982 Jul; 31(13):2273-8. PubMed ID: 6889865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of a novel platinum compound--cis-dichloro (dimethylsulphoxide) (1-beta-D-rybofuranosyl-1,2,4-triazolo-3-arboxyamide) platinum (II)--"Pt-rib-1"--on cell cycle and apoptosis in ClS91 and B16 mouse melanoma in vitro.
    Drewa T; Olszewska-Słonina D; Woźniak A; Styczyński J; Drewa G; Szłyk E; Lakomska I; Kobe J; Czajkowski R
    Acta Pol Pharm; 2004; 61(1):39-44. PubMed ID: 15259856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).
    Gringeri A; Keng PC; Borch RF
    Cancer Res; 1988 Oct; 48(20):5708-12. PubMed ID: 2844391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
    Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH
    Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
    Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
    Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo.
    Gianasi E; Wasil M; Evagorou EG; Keddle A; Wilson G; Duncan R
    Eur J Cancer; 1999 Jun; 35(6):994-1002. PubMed ID: 10533484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
    Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
    Yamada K; Kato N; Takagi A; Koi M; Hemmi H
    Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison in rodents of renal and intestinal toxicity of cisplatin and a new water-soluble antitumor platinum complex: N-methyl-iminodiacetato-diaminocyclohexane platinum (II).
    Newman RA; Khokhar AR; Sunderland BA; Travis EL; Bulger RE
    Toxicol Appl Pharmacol; 1986 Jul; 84(3):454-63. PubMed ID: 3726868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
    Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
    Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.